Given the findings from our in vitro analyses that co-treatment with pomalidomide and GSK126 promotes B-cell differentiation, thereby inhibiting the proliferation of EZH2 mutant DLBCL, we further examined the potential synergistic effects of pomalidomide and GSK126 in vivo. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.